Concentration of Endogenous Secretory Receptor for Advanced Glycation End Products and Matrix Gla Protein in Controlled and Uncontrolled Type 2 Diabetes Mellitus Patients
Abstract
BACKGROUND: Advanced glycation end products (AGE) and their receptor (RAGE) system play an important role in the development of diabetic vascular complications. Recently, an endogenous secretory RAGE (esRAGE) has been identified as a novel splice variant, which lacks the transmembrane domain and is secreted in human sera. Interestingly, it was reported that esRAGE binds AGE ligands and neutralizes AGE actions. Many studies have reported that diabetes mellitus correlates with vascular calcification event and increases progressively in uncontrolled diabetes. Matrix Gla Protein (MGP) is known to act as an inhibitor in vascular calcification. The aim of this study was to observe progress of vascular calcification in uncontrolled diabetes patient by biochemical markers MGP as inhibitor in vascular calcification, via mechanism of AGEs.
METHODS: This study was an observational study with cross sectional design on adult type 2 diabetic male patients who were defined by the 2011 Indonesian diabetes mellitus consensus criteria.
RESULTS: The results of this study showed that there was a positive significant correlation between esRAGE and HbA1C (r=0.651, p=0.009), and negative correlation between MGP and HbA1C (r=-0.465, p=0.081) in controlled diabetes group. In uncontrolled diabetes group there was a positive significant correlation between MGP and HbA1C (r=0.350, p=0.023), despite the fact esRAGE showed no significant correlation with HbA1C. There was no significant difference in level of esRAGE and MGP in controlled and uncontrolled diabetes group, but MGP showed lower level in uncontrolled diabetes group, contrary to esRAGE that had higher concentration.
CONCLUSION: In diabetes condition, complications of vascular calcification are caused by the mechanism of increased AGE formation represented by esRAGE. In diabetes control it is very important to keep the blood vessels from complications caused by vascular calcification.
KEYWORDS: type 2 diabetes mellitus, vascular calcification, esRAGE, MGP, HbA1C
Full Text:
PDFReferences
Pustaka Kedokteran [website on the Internet]. Jakarta: Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia [cited 2009 Oct 1]. Available from: http://penyakitdalam.wordpress.com/.
Goldstein BJ, Muller-Wieland D. Type 2 Diabetes Principle and Practice. 2nd ed. London: Informa Healthcare; 2008. NLMID.
Johnstone MT, Veves A. Diabetes and cardiovascular Disease. 2nd ed. New Jersey: Humana Press ; 2005, NLMID.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 2006; 114: 597-605, CrossRef.
Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: Targets and intervensions. Diabetes Care. 2008; 31 (Suppl 2): S215-21, CrossRef.
Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care. 2009: 32: 2263-8, CrossRef.
Danilevicius CF, Lopes JB, Pereira RM. Bone metabolism and vascular calcification. Braz J Med Biol Res. 2007; 40: 435-42, CrossRef.
Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanism and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004; 24: 1161-70, PMID.
Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev. 2004; 25: 629-72, CrossRef.
Meigs JB, Larson MG, D’Agostino RB, Levy D, Clouse ME, Nathan DM, et al. Coronary artery calcification in type 2 dabetes and insulin resistance: the Framingham offspring study. Diabetes Care. 2002; 25: 1313-9, CrossRef.
Olesen P, Nguyen K, Wogensen L, Ledet T, Rasmussen LM. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am J Physiol Heart Circ Physiol. 2007; 292: H1058-64, CrossRef.
Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, et al. An increase osteoprotegerin serum release characteristizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006; 169: 2236-44, CrossRef.
Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology. 2009; 48: 1190-6, CrossRef.
Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2006; 23: 489-94, CrossRef.
Browner WS, Lui L, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001; 86: 631-7, CrossRef.
DOI: https://doi.org/10.18585/inabj.v5i1.48
Copyright (c) 2013 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
